Format

Send to

Choose Destination
Can J Vet Res. 2018 Jul;82(3):178-183.

Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs.

Author information

1
Department of Clinical Sciences, Colorado State University, 300 West Drake Road, Fort Collins, Colorado 80523, USA.

Abstract

in English, French

The purpose of this study was to determine the pharmacokinetics of cannabidiol (CBD) in healthy dogs. Thirty, healthy research dogs were assigned to receive 1 of 3 formulations (oral microencapsulated oil beads, oral CBD-infused oil, or CBD-infused transdermal cream), at a dose of 75 mg or 150 mg q12h for 6 wk. Serial cannabidiol plasma concentrations were measured over the first 12 h and repeated at 2, 4, and 6 wk. Higher systemic exposures were observed with the oral CBD-infused oil formulation and the half-life after a 75-mg and 150-mg dose was 199.7 ± 55.9 and 127.5 ± 32.2 min, respectively. Exposure is dose-proportional and the oral CBD-infused oil provides the most favorable pharmacokinetic profile.

PMID:
30026641
PMCID:
PMC6038832
[Available on 2019-01-01]
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center